Thermo Fisher unveils new assays; St. Jude launches CRT-D device in Japan;

@FierceMedDev: Despite retiring in 2011, ex-Medtronic CEO Bill Hawkins made about $8M from the company in FY12. Item | Follow @FierceMedDev

 @MarkHFierce: Biomet has cut back its year-over-year losses due to sales growth in its major divisions. Story | Follow @MarkHFierce

 @DamianFierce: J&J's device sales stayed mostly flat as the company's overall earnings dropped. More | Follow @DamianFierce

> Fresh off its $925 million acquisition of One Lambda, Thermo Fisher ($TMO) got a CE mark for its Tacrolimus immunoassay and announced a new generation of its Indiko analyzer, designed to test for drug abuse. News

> St. Jude Medical ($STJ) is launching in Japan the Unify Quadra CRT-D, engineered to treat heart failure by resynchronizing the heart beat. Release

> Becton Dickinson's ($BDX) diagnostics unit got 510(k) clearance for new blood culture bottles, designed for use in sepsis and infection diagnostics. More

> ICU Medical ($ICUI) reported a 3.6% drop in second-quarter earnings but still expects to pull in revenues between $318 million and $325 million for the year. Report

> TriReme Medical got 510(k) clearance for more sizes of Glider PTCA, the world's only torqueable balloon catheter, treating complex percutaneous coronary interventions. Article

> The litigation between Sequenom ($SQNM) and Aria Diagnostics continues, as Sequenom has filed an appeal of a court's ruling that Aria could continue to sell its Down syndrome-related diagnostic while the companies await trial. Item

Biotech News

 @FierceBiotech: DeCode, Genentech find gene mutation marks protection against ‪Alzheimer's‬. More | Follow @FierceBiotech

 @JohnCFierce: Elan is priced for a buyout deal? Oh, my. Who would buy that company just now? Report | Follow @JohnCFierce

 @RyanMFierce: Alnylam up 45% after ALN-TTR02 passes Phase I. Could this be the RNAi drug we've all been waiting for? | Follow @RyanMFierce

> Investors on high alert as D-Day arrives for Vivus's Qnexa. Article

> AZ's MedImmune axing 200 in California R&D restructuring. News

> Analysts' frenzy over PhI success helps ignite Alnylam shares. Story

Pharma News

 @FiercePharma: Simponi‬ for colitis, J&J says: Janssen unit asks FDA to OK new use for Remicade follow-up drug. More | Follow @FiercePharma

> J&J drug sales hold their own, thanks to foreign growth. Report

> AZ puts Brilinta up for another head-to-head fight with Plavix. Article

> Appeals court ruling threatens pay-to-delay deals. News

> Par could fetch up to $2.5B from rival genericsmaker. More

Pharma Manufacturing News

> Lonza seeks growth in China after securing IP. Story

> Feds get conviction in fake J&J test strips case. More

> India regulator orders Aurobindo, others to close 12 plants. Report

> Hospira blames supplier's bad vials for latest recall. Article

Biotech Research News

> Researchers use gene therapy to treat spinal muscular atrophy. Article

> New 'molecular grenade' used to attack tumor cells. Report

> Researcher rebuts rival finding that ovarian stem cells exist. Story

> Rare gene mutation protects against Alzheimer's. More

> Alnylam generates preclinical buzz with RNAi hemophilia drug. News

Suggested Articles

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.

A decade-long study found that patients with early breast cancer may be spared radiation procedures that span the whole breast.